Arthur T. Sands, as CEO, held significant stock positions, peaking at about $1.77 million in January 2021. His insider trading also showed varied activity, with large trades around $2.31 million in February 2021. Over time, he witnessed fluctuations in holdings,...

Arthur T. Sands, as CEO, held significant stock positions, peaking at about $1.77 million in January 2021. His insider trading also showed varied activity, with large trades around $2.31 million in February 2021. Over time, he witnessed fluctuations in holdings, notably a decrease to around $383,000 by September 2024. His stock ownership, combined with compensation that depended heavily on performance, reflects the financial risks typical in pharma. Notably, Sands’ stock values were primarily linked to Lexicon's drug development successes, creating a direct connection between his wealth and the company's performance.